MOU Signing Ceremony Held at Kosin University Gospel Hospital on February 9 (Mon)

Joint Advancement in Clinical Research for NK Cell Combination Therapy Targeting Hepatocellular Carcinoma

"We Will Accelerate the Realization of Precision Medicine Based on Advanced Regenerative Medical Data"

Kosin University Gospel Hospital (Hospital Director Choi Jong-soon) and NKCL Bio Group Co., Ltd. (CEO Shin Dong-hwa) have established a strategic partnership to promote next-generation immune cell therapy.

Kosin University Gospel Hospital announced on the 9th (Mon) that it signed a 'Memorandum of Understanding (MOU) for Activation of Next-Generation Immune Cell Therapy Research' with NKCL Bio Group Co., Ltd. at the hospital's conference room.

This agreement was established to build an organic operational framework between the two organizations, promote exchange and cooperation in the field of next-generation immune cell therapy, and pursue joint advancement toward conquering cancer.

Key Areas of Cooperation

In accordance with the agreement, the two organizations plan to actively cooperate in the following key areas.

●     Clinical Research Cooperation: Mutual information exchange for clinical research on NK cell combination therapy targeting hepatocellular carcinoma

●     Strengthening Technological Capabilities: Joint research and technology exchange to enhance competitiveness in advanced regenerative medical technology

●     Next-Generation Therapeutic Development: Cooperation in developing innovative therapeutics such as tumor microenvironment-overcoming NK cell therapies

●     Precision Medicine Realization: Securing advanced regenerative medical clinical data and implementing customized medical care based on this data

●     Commercialization: Carrying out all necessary tasks for joint technology development and commercialization

In particular, this cooperation focuses on presenting a new treatment alternative for hepatocellular carcinoma, an intractable disease, by utilizing natural killer (NK) cells that directly attack cancer cells.

The combination of Kosin University Gospel Hospital's rich clinical infrastructure and NKCL Bio Group's proprietary NK cell cultivation and therapeutic development technology is expected to generate significant synergy.

Kosin University Gospel Hospital Director Choi Jong-soon stated, "Through this agreement, we have elevated our technological competitiveness in the field of advanced regenerative medicine to the next level," and added, "We will concentrate our research capabilities on developing next-generation immunotherapy that provides practical benefits to patients."

NKCL Bio Group CEO Shin Dong-hwa emphasized, "Through cooperation with excellent clinical sites, we will accelerate the commercialization of NK cell therapeutics and provide innovative treatment solutions befitting the era of precision medicine."